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Abstract
The CDC struggles to predict the upcoming influenza 
viruses resulting in an ineffective influenza vaccine. The 
2019 – 2020 influenza vaccine provides an example of 
vaccine mismatch where the vaccine poorly matches the 
circulating influenza strains. We have created Influenza B 
Epigraph hemagglutinin (HA) immunogens that are 
computationally designed to select the greatest coverage 
of B and T cell epitopes in the natural population. Our 
preliminary data shows Epigraph immunogens induce 
superior cross-reactive antibody responses, overall T cell 
immunity, breadth of T cell epitopes, and protection 
against influenza virus. The primary goal of this study is 
to clone the influenza B Epigraph HA immunogens into 
DNA and Adenoviral mammalian expression systems. 
We will characterize these novel HA immunogens for the 
prevention of influenza B virus infections. Ultimately, we 
seek to develop novel universal influenza vaccines that 
provide a foundation of immunity which protects against 
all past, present, and future influenza viruses.
Introduction
• There are two strains of the Influenza B virus
o B/Yamagata/16/88
o B/Victoria/2/87
• The 2019-2020 flu season had a significantly higher 
incidence of influenza B compared to past flu seasons
Methods
• Three B/Victoria/2/87 and three B/Yamagata/16/88 
epigraph genes were created
• The 6 different epigraph genes were originally 
received in a pMA-T backbone
• Each gene was then amplified, confirmed, and 
ligated into the plasmid pshuttle-CMV
• This plasmid was then amplified, confirmed, and 
linearized with pMeI in order to co-transform each 
pshuttle-CMV epigraph gene and an Adenovirus 
plasmid (pAd-Easy-1) into E.coli cells (BJ5183s)
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Future Steps
After the cloning of pAd-Easy-Vic1, pAd-Easy-Vic2, pAd-
Easy-Vic3, pAd-Easy-YAM1, pAd-Easy-YAM2, pAd-
Easy-YAM3 is complete, each of the six genes will be 
rescued in cell culture, thus creating a mammalian 
expression vector. Each gene will be transfected into 293T 
cells, which are derived from a human embryonic kidney. 
This cell line will be used because of its high 
transfectability and its high titer production when producing 
retroviruses. In order to amplify the virus, consecutive 
infections into greater quantity of cells will be conducted. 
Once the virus is amplified to an adequate concentration, it 
will be moved to the next stage involving infection into 
Mus musculus. After that is successful, we will confirm 
protein expression by Western blot. Western blotting 
involves transferring proteins that are separated by gel 
electrophoresis to a membrane where the proteins are 
analyzed. This research project will take a considerable 
amount of time which is why it was not fully completed 
during this past academic semester.
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Figure 1. Model of Influenza Virus
Figure 3. Positive Influenza virus cases during the 2018-2019 flu 
season where the Influenza B (green) was not significantly prevalent.
Figure 2. Positive Influenza virus cases during the 2019-2020 flu 
season where the Influenza B (green) was heavily prevalent.
Figure 4. Cloning strategy for inserting Yamagata and Victoria strains 
into an Adenoviral Vector system.  
